Drugs / DONQ52
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05425446 | Sep 2022 → Aug 2024 | celiac disease | Chugai Pharmaceutical | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07239336 | Dec 2025 → Jun 2027 expected | celiac disease | Chugai Pharmaceutical | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-12-25 | Chugai Pharmaceutical | Results Chugai’s DONQ52, a Multispecific Antibody under Development for Celiac Disease, Non-Clinical Research Results Published in Nature Communications chugai-pharm.co.jp ↗
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the results of non-clinical research on a multispecific antibody DONQ52 have been published in the Nature Communications. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-12-25 | Chugai Pharmaceutical | Chugai’s DONQ52, a Multispecific Antibody under Development for Celiac Disease, Non-Clinical Research Results Published in Nature Communications chugai-pharm.co.jp ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DONQ52 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05425446 ↗ |
| Route | Subcutaneous | “Subcutaneous (SC) injection” NCT05425446 ↗ |